Lung cancer is a leading cause of death worldwide, due to the fact that most patients are diagnosed in a fairly advanced stage. Screening tests such as sputum citology, chest x-rays or CT scans have their limitations and need further histological confirmation of the diagnosis. Therefore, the need forfast and accurate detection and staging of lung cancer has determined the development of advanced medical procedures using bronchoscopic methods such as white light bronchoscopy, narrow-band imaging, auto-fluorescence bronchoscopy, confocal fluorescence microendoscopy or echoendoscopy.
Introduction
It is a well-known fact that lung cancer (LC) has a globally increased incidence. It is considered that by 2020 there will be 20 million new cases a year, half of them in low and middle income countries [1] .
LC is the most common type of cancer in men, with a 5-year survival rate of only 15%. The survival rate increases to 60-80% in case of early surgically resected LC.
LC is a tumor of extreme severity, 55% of them being discovered in the metastatic stage, 30% in the locally advanced stage, while only 15% are diagnosed in the localized stage. It represents an important cause of death worldwide, with 1,3 million deaths/year globally. LC is responsible for 13% of deaths worldwide, and signifies 28% of all cancer deaths. The mortality of LC is higher than the sum of breast, prostate and colorectal cancer mortality combined [1, 2] .
Early diagnosis of LC means for non-small cell lung cancer (NSCLC) to be diagnosed in 0, I 1 Faculty of Medicine, University "Ovidius" of Constanta or II stages, while small cell lung cancer (SCLC) is preferred to be diagnosed in a limited stage. The ideal case scenario is for all lung cancers to be diagnosed in a preneoplasic stage or in situ carcinoma [3] .
The TNM stadialization of lung cancer is represented in the fi gure 1 and is the following:
T (Tumor) Tis -carcinoma in situ(does not exceed the basal membrane of the epithelium) T1 -tumor size less than or equal to 3 cm across, surrounded by lung or visceral pleura, without invasion proximal to the lobar bronchus.
T1a Tumor size less than or equal to 2 cm; T1b Tumor size more than 2 cm but less than or equal to 3 cm.
T2 -Any of: Tumor size more than 3 cm but less than or equal to 7 cm across;
Involvement of the main bronchus at least 2 cm distal to the carina; Invasion of visceral pleura; Atelectasis/obstructive pneumonitis extending to the hilum but not involving the whole lung.
T2a Tumor size more than 3 cm but less than or equal to 5 cm; T2b Tumor size more than 5 cm but less than or equal to 7 cm.
T3 -Any of: Tumor size more than 7 cm across Invasion into the chest wall, diaphragm, phrenic nerve, mediastinal, pleura or parietal pericardum;
Tumor less than 2 cm distal to the carina, but not involving the carina; Atelectasis/obstructive pneumonitis of the whole lung;
Separate tumor nodule in the same lobe.
T4 -Any of: Invasion of the mediastinum, heart, great vessels, trachea, carina, recurrent; laryngeal nerve, esophagus, or vertebra;
Separate tumor nodule in a diff erent lobe of the same lung. M1b -Distant metastasis [3] .
Figure 1 -LC staging (TNM staging system).
The positive diagnosis of LC always needs bronchoscopy with white light (WLB).
WLB can be used for the diagnosis (including histological assessment) and staging of central and peripheral tumors. This procedure can show 3 types of fi ndings: intraluminal growth, damage of the bronchial wall, deformation of the normal anatomy due to extrinsic compression.
The endobronchial changes that can appear at the WLB are:
1. direct evidence (of the tumor itself):
• endoluminal vegetations;
• endobronchial stenosis due to neoplastic infi ltration; 2. indirect signs of lung cancer:
• extrinsic compression;
• bronchial stiff ness (during inspiration / expiration); • ± alterations of static lung compliance (slow installed in atelectasis);
3. indirect signs of lymph node invasion; 4. accompanying signs of bronchi and of the juxtatumoral lung tissue:
• inflammation / hypersecretion;
• granulation tissue (ongoing or previous) [4] . The endoscopic anomalies in LC after Ryosuka Ono are represented by:
1. tumor: polypoid, nodular, with/without necrosis(figure 2, 3); 3. bronchial obstruction due to tumor, infiltration (figure 6); 4. bronchial stenosis determined infi ltration, compression(fi gure 7); 5. extrinsic compression secondary to lymph node, tumor( fi gure 8) [4] . During bronchoscopy it is possible the prelevation of brochial material for cytological and histological examination. Bronchial aspiration is conducted under visual control of the area with changes that suggest malignancy. The technique requires injection and then aspiration in a container, through the bronchoscope, of 5-10 ml saline solution. The procedure has reduced diagnostic contribution (may increase after bronchial lavage and bronchial brush by increasing the number of exfoliated cells). The major cause of false positives in this case is signifi ed by pavement metaplasia [5] .
Bronchial brush consists of bronchial cells exfoliation, using brushes and their fi xation to slides. This procedure har a signifi cant higher output than bronchial aspirate (positive results in 88-94% of cases) [5] .
Bronchial biopsy has a increased diagnostic accuracy by direct visualization and biopsy of the lesion, washing/aspiration of secretions, blood and necrotic material, "deep" biopsies in necrotic tumors, increased number of biopsies in central tumors (3-4-5) . This procedure off ers histological confi rmation of tumors highlighted by bronchoscopy: 55-85%, but it has a major complication -bleeding [5] .
Transbronchial biopsy (lung/lymph node biopsy) has the following indications:
• diagnosis of tumors developed in the submucosa; • diagnosis of compressive and necrotic tumors; • defi ning the proximal edges of surgical resection; • LC staging through hilar and mediastinal lymph node biopsy (the most important indication).
The procedure has a sensibility of aproximately 50% (in the staging of the mediastinal lymph nodes) with a specificity of 95% and a sensitivity of 57% (17 -80%). There are a few complications such as pneumothorax (1 -4%) and hemoptysis.The purpose of the procedure is to biopsy the peripheral lesions located in the lung parenchyma [6] .
Broncho-alveolar lavage (BAL)
The most important indication of this procedure is the diagnosis of peripheral lung tumors, but it also offers cytology, biochemistry, bacteriology and immunology assessments. BAL has an increased diagnostic accuracy in tumors larger than 3 cm in diameter and adenocarcinoma or broncho-alveolar carcinoma. The most common complications are fever, and impaired, but reversible respiratory tests [7] .
Today we can do in BAL molecular markers like:
• P53 mutations, that appear in central tumors (squamous cell carcinomas), present in approximately 27% of all LC; • K-ras mutations, that are more frequent in peripheral tumors (adenocarcinomas) and the mutation is present in 56% of all LC; • Ag HnRNP A2/B1, that has a sensibility of 96% and a specificity of 82%; • CpG p16, that shows the hypermethilation process in case of LC; • microsatellites mutations models (LOH) in 4 out of 8 loci may lead to cancer; with a sensibility of 73,9% and a specificity of 76,5% there are more common in peripheral tumors compared to central ones (100% vs 29%;p= 0,032) [2] . Electromagnetic Navigation Bronchoscopy (ENB) is a new method based on 3D-CT images and virtual bronchoscopy performed in real time. It is addressed to the peripheral tumor masses, that can not be biopsied using a standard bronchoscope and the procedure increases the diagnosis rate of transbronchial biopsy.
ENB has a diagnose rate of approximately 70%, and presents a major advantage: enough tissue for histopathologicalexamination and molecular tests. The complications are similar to conventional bronchoscopy, but there is a major drawback, the costs [8, 9] .
Autofluorescence bronchoscopy (AFB) is another investigation that helps at diagnosis of early lung cancer. Endoscopical aspects obtain in AFB are divided into 3 classes: class I -normal aspesct, class II: inflammation and mild dysplazia, class III: moderate or severe dysplasia, carcinoma in situ, invasive carcinoma. AFB helps the diagnosis of moderate / severe dysplasia (increase in sensitivity from 9% to 65%), and of carcinoma in situ (increase in sensitivity from 4% to 100, low specificity, 1/3 false positives), but is also used in preoperative screening (evaluating patients with operable cancer) -marking the resection lines or in the evaluation of lung cancer extention of endoscopically visible tumors [2, 10, 11, 12] .
Narrow-Band Imaging Bronchoscopy(NBI) may be used for the visualization of superficial capillary circulation and submucosa. Herth et al concluded that NBI offers better results in the diagnosis of intraepithelial neoplasia.
While WLB's sensibility is only of 18% andAFB's relative sensibility (compared to WLB) is 3.7(p=0,005), NBI's relative sensibility (compared to WLB) is of 3.0 (p=0,03). NBI's specificity is significantly increased compared to AFB, but there are no statistic differences when it comes to sensibility. Combining AFB with NBI does not bring any additional benefits [13] .
Confocal Fluorescence Microendoscopy (CFM) is used in identifying cellular and subcellular microstructures, offeringblur-free, high-resolution images of living andexvivo biologic samples by reducing aut-of-focus light from above and below the focal plane.Offers a stack of deep-resolved optical images without physical sectioning.
Thiberville concluded that CFM can be used in diagnosing of dysplastic lesions and can offer a strong correlation between the number of smoked cigarettes/ day and the number of mobile macrophages noticed in vivo or the extent of macrophage alveolitis [2, 10] .
Echoendoscopy (EUS +/-EBUS + FNA) is indicated in the diagnosis and staging of LC: LC with hilar and/or mediastinal lymphadenopathy and also LC with positive PET-CT.
The accuracy of stadialization is essential for treatment. The CT and PET-CT are characterized the lung tumor (figure 9), mediastinum (figure 10) and metastasis( fi gure 11). EBUS and EUS permited obtaining of tissue for histological examination with confi rmation or exclusion of neoplastic aff ection. The chance of metastasis is around 50-80%, but sometimes exist false positive results (the adenomegaly is done by infl ammation, no by lymphatic metastasis). Also EUS permits the investigation of left adrenal gland [4] . Echoendoscopy permit the evalution of the mediastinal lymphnodes (table 1) , with diff erentiation of N1 to N2.
The In patients with suspected or proven<3cm peripheral NSCLC with normal mediastinal and hilar nodes at CT and/or PET, we suggest initiation of therapy without further mediastinal staging (Recommendation grade C). A complete assessment of mediastinal and hilar nodal stations, and sampling of at least three different mediastinal nodal stations (4 R, 4L, 7)is suggested in patients with NSCLC and an abnormal mediastinum by CT or CT-PET (Recommendation grade D).
For diagnostic purposes, in patients with a centrally located lung tumor that is not visible at conventional bronchoscopy, endosonography is suggested, provided the tumor is located immediately adjacent to the larger airways (EBUS) or esophagus (EUS-(B)) (Recommendation grade D).
In patients with a left adrenal gland suspected for distant metastasis we suggest performance of EUS-FNA (Recommendation grade C), whilethe use of EUS-B with a transgastric approach is at present experimental (Recommendation grade D).
In conclusions, the early diagnosis and screening of LC are a continuous challenge.
Early diagnosis and treatment of LC assure an 3-4 times increased 5-year survival, which is a good reason for research to be continued in this area of interest.
